The imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of immunomodulatory therapies.
We also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them. Please find out more about the initial challenge, our approach and objectives, as well as the intended impact below.
A significant challenge facing the development of new therapies is and remains their preclinical evaluation in terms of efficacy and safety. The greatest problem here is the complexity of the human immune system.
Approach and Objectives
The overall aim of imSAVAR is to improve the ability to predict adverse immune-related toxicities and establish a standard approach to immune safety assessment.
The idea of the imSAVAR consortium is that this initial project will evolve into a community and an ecosystem around the topic of immune safety assessment.
The Innovative Medicines Initiative (IMI) is the world's biggest public-private partnership (PPP) in the life sciences. ImSAVAR benefits from 11 million euros IMI2 funding. The industrial partners contribute the same sum as in-kind contribution.